← Back to Analyst Consensus 
SANA Buy
Sana Biotechnology, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Apr 14, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jan 6, 2026 | B of A Securities | maintain | Buy → Buy | $7 | 53% |
| Nov 7, 2025 | Wedbush | maintain | Outperform → Outperform | $6 | 58% |
| Nov 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Oct 30, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $8 | 46% |
| Sep 24, 2025 | Wedbush | initiate | — → Outperform | $5 | 58% |
| Jun 24, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $5 | 53% |
| Apr 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Mar 18, 2025 | Citizens Capital Markets | upgrade | Market Perform → Market Outperform | $5 | 49% |
| Mar 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Mar 14, 2025 | Jefferies | initiate | — → Buy | $7 | 52% |
| Jan 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Jan 8, 2025 | TD Cowen | upgrade | Hold → Buy | $0 | 54% |
| Nov 27, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Nov 5, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Nov 5, 2024 | JMP Securities | downgrade | Market Outperform → Market Perform | $0 | 53% |
| Aug 9, 2024 | Citigroup | maintain | Buy → Buy | $15 | 54% |
| Aug 9, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| May 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Mar 1, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $15 | 53% |
| Mar 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Jan 16, 2024 | HC Wainwright & Co. | upgrade | Neutral → Buy | $12 | 44% |
| Oct 12, 2023 | JMP Securities | maintain | Market Outperform → Market Outperform | $8 | 53% |
| Sep 25, 2023 | JMP Securities | initiate | — → Market Outperform | $9 | 53% |
| Sep 5, 2023 | Citigroup | initiate | — → Buy | $8 | 54% |
| Aug 14, 2023 | TD Cowen | initiate | — → Market Perform | $0 | 54% |
| May 2, 2023 | HC Wainwright & Co. | initiate | — → Neutral | $0 | 44% |
| Jan 24, 2023 | Morgan Stanley | maintain | — → Overweight | $13 | 54% |
| Nov 3, 2022 | Goldman Sachs | maintain | — → Neutral | $6 | 54% |
| May 17, 2022 | Morgan Stanley | maintain | — → Overweight | $15 | 54% |
| Aug 6, 2021 | Goldman Sachs | maintain | — → Neutral | $34 | 54% |
| Mar 1, 2021 | JP Morgan | initiate | — → Neutral | $35 | 54% |
| Mar 1, 2021 | Morgan Stanley | initiate | — → Overweight | $40 | 54% |
| Mar 1, 2021 | Goldman Sachs | initiate | — → Neutral | $40 | 54% |
Price Target Trend
May 3, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days